Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 0.41 |
| ▸ | LCK | P06239 | 4/20 | 0.41 |
| ▸ | CSF1R | P07333 | 4/20 | 0.41 |
| ▸ | FLT1 | P17948 | 4/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.41 |
| ▸ | MET | P08581 | 3/20 | 0.41 |
| ▸ | FYN | P06241 | 3/20 | 0.41 |
| ▸ | LYN | P07948 | 3/20 | 0.41 |
| ▸ | BLK | P51451 | 3/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | FES | P07332 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | FER | P16591 | 2/20 | 0.41 |
| ▸ | MARK3 | P27448 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | FRK | P42685 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28802216 | 0.92 | KDR (0.41) | KITLCKCSF1RFLT1ALK | |
| SCHEMBL984454 | 0.89 | FYN (0.46) | FYNKCNN4CDK8 | |
| SCHEMBL985955 | 0.89 | JAK2 (0.40) | KITLCKCSF1RFLT1ALK | |
| SCHEMBL982851 | 0.89 | GSK3B (0.43) | MAP4K4MARK3MAP4K2MARK2TAOK1 | |
| SCHEMBL984929 | 0.88 | KCNN4 (0.42) | FYNMAP4K4KCNN4 | |
| SCHEMBL985666 | 0.88 | KCNN4 (0.38) | FYNKCNN4KDRPDGFRB | |
| SCHEMBL985133 | 0.87 | KCNN4 (0.41) | FYNMAP4K4KCNN4 | |
| SCHEMBL986578 | 0.87 | KCNN4 (0.41) | FYNKCNN4KDRPDGFRB | |
| SCHEMBL987882 | 0.87 | MAPT (0.40) | FYNMAP4K4KCNN4KDRPDGFRB | |
| SCHEMBL987266 | 0.87 | SLC2A1 (0.44) | METFYNKCNN4KDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101479255-B | C-MET protein kinase inhibitors for the treatment of proliferative disorders | VERTEX PHARMA | 2013-05-01 | — | — | CN | claimed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | claimed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | claimed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | claimed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | claimed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | claimed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | KIT 261/4885LCK 162/4885CSF1R 724/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | KIT 261/4885LCK 162/4885CSF1R 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.